Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

The recent FDA approval of lenacapavir is encouraging in its promise of long-term HIV prevention but might not be available for the vast majority of people in the US.

The United States Food and Drug Administration (FDA) has approved a twice-a-year drug to be used to prevent HIV.

The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...

HIV and global health activists say the deployment of Gilead’s twice-a-year HIV prevention shot is the world’s best chance to beat back the virus and prevent new infections.